Whalesbook
Fredun Pharmaceuticals' Board of Directors convened on March 25, 2026, approving the allotment of 1,06,668 equity shares. This move follows the company's receipt of ₹10.00 crore in balance consideration for the conversion of warrants. The capital infusion is set to bolster the company's financial standing.
These 1,06,668 new shares are issued upon the conversion of warrants initially allotted to promoters on December 29, 2025. While the new shares will rank pari passu, meaning they hold the same rights as existing equity, this issuance expands Fredun Pharma's total outstanding equity. This could potentially impact earnings per share calculations if profits do not grow at a similar rate.
The company had originally allotted 1,60,000 warrants to its promoters on December 29, 2025. Today's decision details the conversion of a significant portion of these into equity shares.
With this issuance, 1,06,668 new equity shares are added to Fredun Pharma's total share capital, growing its overall equity base. A balance of 53,332 warrants remains outstanding.
Fredun Pharmaceuticals operates in India's competitive pharmaceutical sector, alongside peers like Laurus Labs, which focuses on APIs and formulations, and Ipca Laboratories, known for its broad product portfolio serving both domestic and international markets.
Looking ahead, investors will monitor how Fredun Pharma strategically utilizes the ₹10.00 crore raised and any future decisions concerning the remaining 53,332 warrants. The company's upcoming financial performance and any new strategic announcements will also be closely watched.